Expansion of state-of-the-art MR imaging infrastructure for pulmonary disease stratification: POLARIS
Lead Research Organisation:
University of Sheffield
Department Name: Infection Immunity & Cardiovasc Disease
Abstract
Summary of POLARIS
The unique combination of expertise in technology development and the proven ability to translate new technologies into pioneering clinical studies at the University of Sheffield forms the basis of this application for funding. We have long-standing high-level collaborations with both Hospital Trusts in Sheffield (Sheffield Teaching Hospital and Sheffield Children's Hospital) that allow us to apply our developments in all age groups. This has established Sheffield as a national clinical referral centre for image based understanding of lung diseases, but our work has also enabled other centres within the UK to roll out the methods for the benefit of a much wider group of patients. This application is particularly timely with the award of the NIHR Research Professorship to Jim Wild in 2013, which will facilitate the national uptake of the technology at other centres. The expansion of our gas polarisation facilities enabled by this grant will have many benefits for our collaborating centres including creation of a national distribution facility for hyperpolarised gases for those centres that don't have their own polarisation facilities. The ongoing methodological research, clinical evaluations and work with drug companies performed on the planned new state-of-the art 1.5T scanner will ensure that the UK becomes the leading nation in this important area of diagnostic medicine.
The unique combination of expertise in technology development and the proven ability to translate new technologies into pioneering clinical studies at the University of Sheffield forms the basis of this application for funding. We have long-standing high-level collaborations with both Hospital Trusts in Sheffield (Sheffield Teaching Hospital and Sheffield Children's Hospital) that allow us to apply our developments in all age groups. This has established Sheffield as a national clinical referral centre for image based understanding of lung diseases, but our work has also enabled other centres within the UK to roll out the methods for the benefit of a much wider group of patients. This application is particularly timely with the award of the NIHR Research Professorship to Jim Wild in 2013, which will facilitate the national uptake of the technology at other centres. The expansion of our gas polarisation facilities enabled by this grant will have many benefits for our collaborating centres including creation of a national distribution facility for hyperpolarised gases for those centres that don't have their own polarisation facilities. The ongoing methodological research, clinical evaluations and work with drug companies performed on the planned new state-of-the art 1.5T scanner will ensure that the UK becomes the leading nation in this important area of diagnostic medicine.
Technical Summary
SEE SUMMARY
Planned Impact
This investment in imaging, hyperpolarisation and computing infrastructure will help consolidate Sheffield and the UK as an international centre of excellence for hyperpolarised MRI and a clinical centre of excellence for pulmonary imaging.
Organisations
- University of Sheffield (Lead Research Organisation)
- University of Glasgow (Collaboration)
- GE Healthcare Life Sciences (Collaboration)
- Galapagos NV (Collaboration)
- Kiel University (Collaboration)
- AstraZeneca (Collaboration)
- McMaster University (Collaboration)
- Cincinnati Children's Hospital Medical Center (Collaboration)
- Cardiff University (Collaboration)
- Hannover Medical School (Collaboration)
- Columbia University (Collaboration)
- Aarhus University (Collaboration)
- University of Manchester (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Newcastle University (Collaboration)
- Columbia University Medical Center (Collaboration)
- University Hospital Schleswig-Holstein -Kiel (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- GE Healthcare Limited (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
- ROYAL PAPWORTH HOSPITAL NHS FOUNDATION TRUST (Collaboration)
Publications
Alabed S
(2022)
Quality of reporting in AI cardiac MRI segmentation studies - A systematic review and recommendations for future studies.
in Frontiers in cardiovascular medicine
Alabed S
(2022)
Machine learning cardiac-MRI features predict mortality in newly diagnosed pulmonary arterial hypertension.
in European heart journal. Digital health
Alabed S
(2020)
Cardiac Magnetic Resonance in Pulmonary Hypertension-an Update.
in Current cardiovascular imaging reports
Alabed S
(2021)
Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
in JACC. Cardiovascular imaging
| Guideline Title | Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. |
| Description | Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Guidelines for clinical imaging of pulmonary hypertension |
| Description | MHRA specials licence for hyperpolarised gas manufacture - Pathway for diagnostic lung imaging with hyperpolarised gases |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Opened a diagnostic pathway for referral of patients with respiratory disease for sensitive functional lung imaging using hyperpolarised gas MRI in Sheffield. This is a world first to clinical practice for this technology. Patients have been referred from Sheffield, Manchester, Leeds, Bradford, Royal Brompton Lomdon, Nottingham and Leicester NHS hospitals. |
| Description | MRC Review of Positron Emission Tomography (PET) within The Medical Imaging Research Landscape |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://mrc.ukri.org/publications/browse/review-of-pet-within-the-medical-imaging-landscape/ |
| Description | Protocols for multi-site trials using hyperpolarized 129 Xe MRI for imaging of ventilation, alveolar-airspace size, and gas exchange: A position paper from the 129 Xe MRI clinical trials consortium |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | Protocols are being sued to set clinical xenon lung MRI practices up |
| Guideline Title | Expanding Applications of Pulmonary MRI in the Clinical Evaluation of Lung Disorders: Fleischner Society Position Paper. |
| Description | White papers for lung MRI, imaging in pulmonary hypertension and xenon MRI |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Solutions for radiation free clinical diagnostic lung imaging with MRI |
| Description | 1 H MR methods for assessment of lung structure and function ¿ a study of the after effects of COVID-19 infection on the lungs of healthy su |
| Amount | £40,000 (GBP) |
| Organisation | GE Healthcare Limited |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 07/2021 |
| Description | A mechanistic, non-invasive pilot study of effects of mepoluzimab on airways of subjects with COPD, and the relationship to eosinophilia |
| Amount | £735,408 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 08/2020 |
| End | 03/2021 |
| Description | Assessing the effects of personalised airway clearance regimens in young people with Primary Ciliary Dyskinesia. |
| Amount | £324,553 (GBP) |
| Funding ID | NIHR301558 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2024 |
| Description | C-MORE Capturing MultiORgan Effects of COVID-19 - TIER 3 study of PHOSP 168777 |
| Amount | £27,500 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 04/2021 |
| Description | Computational imaging assessment of pulmonary haemodynamics for non-invasive diagnosis of patients with pulmonary hypertension |
| Amount | £15,715 (GBP) |
| Organisation | Sheffield Hospitals Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 09/2015 |
| Description | Developing an intelligent tool to improve prognostic and treatment response assessment on cardiac MRI data with machine learning |
| Amount | £500,539 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 06/2021 |
| Description | Development and application of multi-modality image processing methods for quantitative structural and functional understanding of lung diseases |
| Amount | £200,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 09/2018 |
| End | 09/2020 |
| Description | Development and application of multi-modality image processing methods for quantitative structural and functional understanding of lung diseases |
| Amount | £200,000 (GBP) |
| Funding ID | BIDS3000032592 |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 09/2018 |
| End | 09/2020 |
| Description | Donald Heath Fellowships-Actelion funding |
| Amount | £0 (GBP) |
| Organisation | Actelion Pharmaceuticals Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 09/2020 |
| Description | ECMC Renewal Application |
| Amount | £100,997 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2022 |
| Description | EU/ERS RESPIRE3 Marie Sklodowska-Curie COFUND Postdoctoral Global Research Fellowship |
| Amount | £208,000 (GBP) |
| Organisation | Marie Sklodowska-Curie Actions |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | |
| Description | Evaluation of the microstructure and functional changes in the lung before and after major abdominal surgery, anaesthesia and mechanical ventilation, using functional hyperpolarised helium and xenon MRI |
| Amount | £18,980 (GBP) |
| Organisation | Association of Anaesthetists of Great Britain and Ireland (AAGBI) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 12/2017 |
| Description | Extending the clinical reach of MRI scanning through innovative low-field engineering and hyperpolarised xenon technology |
| Amount | £2,977,386 (GBP) |
| Funding ID | EPSRC_PP_175467 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 04/2028 |
| Description | Free-breathing lung MRI: Feasibility in Pre-school Aged Children with Cystic Fibrosis |
| Amount | £13,152 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 07/2023 |
| Description | Free-breathing, Rapid, Multi-nuclear MRI of lung structurefunction in infants |
| Amount | £241,429 (GBP) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 07/2019 |
| End | 08/2022 |
| Description | Genentech imaging study costs - RECEAD UK |
| Amount | £149,302 (GBP) |
| Organisation | Genentech, Inc |
| Sector | Private |
| Country | United States |
| Start | 03/2022 |
| End | 06/2022 |
| Description | HypErpolarised Xenon Magnetic Resonance PuLmonary ImAging In PatieNts with Long-COVID (EXPLAIN) (Additional funding for 172356) |
| Amount | £398,220 (GBP) |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2021 |
| End | 01/2023 |
| Description | HypErpolarised Xenon Magnetic Resonance PuLmonary Imaging in PAtIeNts with Long-COVID (EXPLAIN) |
| Amount | £1,860,064 (GBP) |
| Funding ID | COV-LT2-0049 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2021 |
| End | 01/2024 |
| Description | Hyperpolarised gas MRI and multiple breath inert gas washout to improve management and understanding of cystic fibrosis lung disease |
| Amount | £264,253 (GBP) |
| Funding ID | ICA-CDRF-2015-01-027 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 04/2019 |
| Description | ICA Programme Clinical Doctoral Research Fellowship-Laurie Smith |
| Amount | £0 (GBP) |
| Funding ID | ICA-CDRF-2015-01-027 |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 04/2019 |
| Description | IICD: Jim Wild- Astrazeneca- "Novelty Imaging Study" |
| Amount | £668,365 (GBP) |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 07/2023 |
| Description | Image Analysis budget for C-MORE |
| Amount | £10,000 (GBP) |
| Funding ID | HBR03920 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 05/2021 |
| Description | Image-guided radiotherapy |
| Amount | £97,389 (GBP) |
| Organisation | Sheffield Hospitals Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 04/2019 |
| Description | Imaging a better future for Sheffield patients with thoracic malignancies undergoing radiotherapy |
| Amount | £8,000 (GBP) |
| Organisation | Sheffield Hospitals Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 07/2022 |
| Description | Improving detection of pulmonary arterial hypertension in systemic sclerosis patients using hyperpolarised gas magnetic resonance imaging. |
| Amount | £191,583 (GBP) |
| Funding ID | 23100014 |
| Organisation | Heart Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 08/2025 |
| Description | Isabela Imaging Study |
| Amount | £501,592 (GBP) |
| Organisation | Galapagos NV |
| Sector | Private |
| Country | Belgium |
| Start | 02/2020 |
| End | 12/2021 |
| Description | MICA: Non-invasive quantitative ventilation imaging by MRI of fluorocarbon gases |
| Amount | £1,126,469 (GBP) |
| Funding ID | MR/N018915/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 12/2022 |
| Description | MRC Proposal - Sheffield and Newcastle |
| Amount | £216,556 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2019 |
| Description | MRC Proposal-Sheffield and Newcastle |
| Amount | £0 (GBP) |
| Funding ID | MR/N018915/1 |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Human Nutrition Research Group |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2019 |
| Description | MRI-COVID-LUNG ¿ pilot study of lung pathophysiology in acute SARS-CoV-2 |
| Amount | £36,181 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 11/2020 |
| End | 06/2022 |
| Description | MSKCC costing for Research Component |
| Amount | £22,760 (GBP) |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Sector | Academic/University |
| Country | United States |
| Start | 02/2018 |
| End | 06/2018 |
| Description | PHOSP-COVID Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes |
| Amount | £8,914,274 (GBP) |
| Funding ID | MR/V027859/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 03/2026 |
| Description | PILOT STUDY - STRUCTURAL MAGNETIC RESONANCE LUNG IMAGING IN COMPARISON WITH COMPUTED TOMOGRAPHY LUNG IMAGING IN INFANTS WITH BRONCHOPULMONARY DYSPLASIA |
| Amount | £2,575 (GBP) |
| Organisation | Sheffield Children's Hospital |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 06/2022 |
| End | 01/2023 |
| Description | Polariser project - UCL |
| Amount | £239,000 (GBP) |
| Organisation | Northern Health and Social Care Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2020 |
| End | 09/2025 |
| Description | Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis |
| Amount | £430,915 (GBP) |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2023 |
| End | 08/2027 |
| Description | Recovery and reuse of 129Xe in hyperpolarised MRI |
| Amount | £113,422 (GBP) |
| Organisation | Linde Group |
| Sector | Private |
| Country | Global |
| Start | 05/2016 |
| End | 05/2024 |
| Description | Repeatability of magnetic resonance imaging cardiopulmonary metrics in pulmonary arterial hypertension - Implications for trial design |
| Amount | £239,067 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 01/2015 |
| End | 01/2017 |
| Description | Repeatibility of magnetic resonance imaging cardiopulmonary metrics in pulmonary arterial hypertension-implications for trial design |
| Amount | £239,067 (GBP) |
| Funding ID | GLAXOSMITHKLINE |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 01/2015 |
| End | 01/2017 |
| Description | Research Radiographer |
| Amount | £90,000 (GBP) |
| Funding ID | L.GB.09.2014.7802 |
| Organisation | Bayer |
| Sector | Private |
| Country | Germany |
| Start | 03/2015 |
| End | 03/2018 |
| Description | Research grant form Boehringer-Ingelheim. 'Assessment of structural and functional lung MR imaging in the monitoring of treatment in IPF |
| Amount | £250,000 (GBP) |
| Organisation | Boehringer Ingelheim |
| Sector | Private |
| Country | Germany |
| Start | |
| Description | Respiratory Health in Preterm Neonates (RHINO) |
| Amount | £80,028 (GBP) |
| Funding ID | MR/M022552/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 08/2019 |
| Description | STH20679 Using benralizumab to explore treatment response patterns in functional lung MRI and advance measures of lung function |
| Amount | £266,192 (GBP) |
| Funding ID | D4250C00079 |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 03/2021 |
| Description | Standardised ventilation perfusion and structure (VIPS) MRI platform for monitoring cystic fibrosis lung disease |
| Amount | £93,759 (GBP) |
| Organisation | Cystic Fibrosis Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2017 |
| End | 02/2019 |
| Description | TRISTAN V3 |
| Amount | £761,496 (GBP) |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 01/2017 |
| End | 12/2021 |
| Description | The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID. |
| Amount | £2,014,983 (GBP) |
| Funding ID | MR/W006111/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 03/2023 |
| Description | Towards functional lung imaging for MR-Linac based image-guided radiotherapy |
| Amount | £3,999,800 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 11/2018 |
| Description | Validation of a non-invasive magnetic resonance image based computational tool for the diagnosis of PH. |
| Amount | £48,028 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 05/2018 |
| Description | WPH CC Research Fellowship in Radiotherapy Imaging |
| Amount | £43,891 (GBP) |
| Funding ID | 111221 |
| Organisation | Sheffield Hospitals Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 09/2015 |
| Description | Wellcome Trust - Clinical Research Training Fellowship. Pulmonary Vascular Disease: Computational Modelling and large data analytics |
| Amount | £827,821 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 01/2022 |
| Description | Whole heart, four-dimensional flow magnetic resonance imaging for accurate assessment of right and left heart flow haemodynamics |
| Amount | £25,400 (GBP) |
| Funding ID | SGL018\1100 |
| Organisation | Academy of Medical Sciences (AMS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 06/2021 |
| Description | Xenon-129 brain coil for 3T |
| Amount | £20,000 (GBP) |
| Organisation | Department of Health (DH) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 03/2019 |
| Description | Yorkshire Cancer Research (YCR) Catalyst for Innovation in Cancer Care and Treatment in Sheffield (YCR CONNECTS) |
| Amount | £4,549,817 (GBP) |
| Organisation | Yorkshire Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2022 |
| Description | Yorkshire Cancer Research. 'Lung MRI for risk stratification to select non-small cell lung cancer patients for radical treatment |
| Amount | £348,000 (GBP) |
| Organisation | Yorkshire Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Title | Portable xenon polariser |
| Description | Development of a portable xenon polariser that can be taken to novice sites waiting to access the technology for clinical lung imaging |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Lung images acquired with xenon at papworth hospital Build of a polariser for UCL BRC |
| Title | Xenon clinical trials consortium imaging database |
| Description | Database of xenon lung ventialtion images from 6 centres |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Open access database for training AI algorithms for segmeting ventilation images |
| Description | Aarhus University xenon poalriser and MRI pulse sequences |
| Organisation | Aarhus University |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | Enabled xenon MRI in Danish medical centre with POLARIS xenon polariser and mRI pulse sequences |
| Collaborator Contribution | New collaboration for xenon lung MRI in Denmark , co supervision of PhD student |
| Impact | Joint PhD student New site enabled for xenon multi centre imaging |
| Start Year | 2021 |
| Description | Astra Zeneca NOVELTY AdPRO study |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Performing a xenon MRI and lung function deep phenotyping sub-study on the asthma COPD NOVELTY study |
| Collaborator Contribution | Lead on lung MRI |
| Impact | ERS abstracts |
| Start Year | 2020 |
| Description | CHANGE-MRI |
| Organisation | Hannover Medical School |
| Department | Radiology Centre |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Definition and implementation of a multi site clinical evaluation of MRI perfusion imaging for screening of Chronic Thromboembolic Lung Disease |
| Collaborator Contribution | Sole UK partner - acquisition of imaging data and methodology development |
| Impact | None yet |
| Start Year | 2016 |
| Description | COVID-ILD |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Lead on lung MRI study central to this UKRI multi centre clinical study evaluating the incidence of interstitial lung disease post COVID |
| Collaborator Contribution | Large national clinical research cosnortium |
| Impact | Established first UK multi centre platform study for xenon MRI |
| Start Year | 2020 |
| Description | Collaboration with GE Healthcare on developing 129Xe MRI hardware on new 1/5T scanner |
| Organisation | GE Healthcare Life Sciences |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Design, testing, iterative feedback and evaluation of new hardware for xenon MRI on new GE 1.5T and PET-MR MRI scanners (2018) , (2021) |
| Collaborator Contribution | Supply of base MRI system and multinuclear MRI hardware |
| Impact | First 129Xe images at Sheffield Northern General Hospital acquired in 2017 First 129Xe images at Royal Hallamshire Hospital PET-MRI acquired in 2017 |
| Start Year | 2013 |
| Description | Columbia University NYC polariser collaboration |
| Organisation | Columbia University Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Installed POLARIS xenon polariser and POLARIS pulse sequences for MRI of xenon |
| Collaborator Contribution | New clinical site for xenon MRI |
| Impact | Xenon MRI enabled in clinical site in US leading medical centre |
| Start Year | 2020 |
| Description | EXPLAIN - NIHR LONG COVID XENION MRI STUDY |
| Organisation | University of Oxford |
| Department | Oxford Hub |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My group provide the xenon lung MRI methodology that underpins this study |
| Collaborator Contribution | Enabled scanning techniques for xenon MRI in Oxford Act as central image processing hub Sheffield is the second clincial recruitment site |
| Impact | paper in Radiology |
| Start Year | 2021 |
| Description | Galapagos pharmaceuticals |
| Organisation | Galapagos NV |
| Country | Belgium |
| Sector | Private |
| PI Contribution | Use of UoS 129Xe lung MRI as outcome measure in a clinical trial of an ILD drug |
| Collaborator Contribution | Appended an imaging outcome measure sub study to an existing clinical trial of a new therapeutic for IPF - https://www.glpg.com/IPF |
| Impact | None yet |
| Start Year | 2019 |
| Description | Mc Master University Canada |
| Organisation | McMaster University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Implementation of Sheffield lung xenon MRI protocols at a new site |
| Collaborator Contribution | Clinical evaluation of Sheffield lung MRI protocols |
| Impact | Ongoing collaborative research |
| Start Year | 2021 |
| Description | PHOSP COVID /CMORE project |
| Organisation | University of Leicester |
| Department | Leicester Medical School |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Coordinator on lung imaging WP Coordinator for CMORE multi organ sub study |
| Collaborator Contribution | Large UK national COVID clinical study |
| Impact | conference abstracts |
| Start Year | 2020 |
| Description | RHINO |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our technology formed an essential component of the MRC award to Prof. Sailesh Kotecha for the RHINO (Respiratory Health Outcomes in Neonates) study. Pilot study from this study inidicates sub-clinical ventilation heterogeneity and microstructural differences in small airways of teenagers born pre-term. |
| Collaborator Contribution | RHINO have recruited 40+ subjects that we have scanned in order for us to collect this data. |
| Impact | N/A |
| Start Year | 2017 |
| Description | Sloan Kettering, New York |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Built RF coil for hyeperpolarised 13C breast MRI for group of Kayvan Kavani |
| Collaborator Contribution | Provided definition of clinical need for new coil |
| Impact | ISMRM abstract Draft paper to MRM Novel RF coil design IP owned by University of Sheffield |
| Start Year | 2019 |
| Description | UCL NIHR BRC |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Build of a xenon polariser for UCL NIHR BRC |
| Collaborator Contribution | Contract to build of a xenon polariser for UCL NIHR BRC |
| Impact | NA yet |
| Start Year | 2019 |
| Description | UK Pulmonary Hypertension MR imaging collaboration |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I have been proactive in standardising and translating MRI protocols for pulmonary disease across all UK centres. I was asked by Prof Nick Morrell in Cambridge, to lead an imaging study with a standardised MR protocol based around the MRC funded national pulmonary arterial hypertension cohort study of which he is the PI. A cardio-pulmonary MR protocol has been drawn up and I am currently in the process of implementing this MR protocol in all of the UK PH clinical centres. |
| Collaborator Contribution | Input on MR protocol design Patient recruitment |
| Impact | Standardised UK Pulmonary Hypertension MRI protocol Basis for clinical trials of new therapies for PH with imaging outcomes |
| Start Year | 2014 |
| Description | UK Pulmonary Hypertension MR imaging collaboration |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I have been proactive in standardising and translating MRI protocols for pulmonary disease across all UK centres. I was asked by Prof Nick Morrell in Cambridge, to lead an imaging study with a standardised MR protocol based around the MRC funded national pulmonary arterial hypertension cohort study of which he is the PI. A cardio-pulmonary MR protocol has been drawn up and I am currently in the process of implementing this MR protocol in all of the UK PH clinical centres. |
| Collaborator Contribution | Input on MR protocol design Patient recruitment |
| Impact | Standardised UK Pulmonary Hypertension MRI protocol Basis for clinical trials of new therapies for PH with imaging outcomes |
| Start Year | 2014 |
| Description | UK Pulmonary Hypertension MR imaging collaboration |
| Organisation | Royal Papworth Hospital NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I have been proactive in standardising and translating MRI protocols for pulmonary disease across all UK centres. I was asked by Prof Nick Morrell in Cambridge, to lead an imaging study with a standardised MR protocol based around the MRC funded national pulmonary arterial hypertension cohort study of which he is the PI. A cardio-pulmonary MR protocol has been drawn up and I am currently in the process of implementing this MR protocol in all of the UK PH clinical centres. |
| Collaborator Contribution | Input on MR protocol design Patient recruitment |
| Impact | Standardised UK Pulmonary Hypertension MRI protocol Basis for clinical trials of new therapies for PH with imaging outcomes |
| Start Year | 2014 |
| Description | UK Pulmonary Hypertension MR imaging collaboration |
| Organisation | University of Cambridge |
| Department | School of Clinical Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I have been proactive in standardising and translating MRI protocols for pulmonary disease across all UK centres. I was asked by Prof Nick Morrell in Cambridge, to lead an imaging study with a standardised MR protocol based around the MRC funded national pulmonary arterial hypertension cohort study of which he is the PI. A cardio-pulmonary MR protocol has been drawn up and I am currently in the process of implementing this MR protocol in all of the UK PH clinical centres. |
| Collaborator Contribution | Input on MR protocol design Patient recruitment |
| Impact | Standardised UK Pulmonary Hypertension MRI protocol Basis for clinical trials of new therapies for PH with imaging outcomes |
| Start Year | 2014 |
| Description | UK Pulmonary Hypertension MR imaging collaboration |
| Organisation | University of Glasgow |
| Department | School of Medicine Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I have been proactive in standardising and translating MRI protocols for pulmonary disease across all UK centres. I was asked by Prof Nick Morrell in Cambridge, to lead an imaging study with a standardised MR protocol based around the MRC funded national pulmonary arterial hypertension cohort study of which he is the PI. A cardio-pulmonary MR protocol has been drawn up and I am currently in the process of implementing this MR protocol in all of the UK PH clinical centres. |
| Collaborator Contribution | Input on MR protocol design Patient recruitment |
| Impact | Standardised UK Pulmonary Hypertension MRI protocol Basis for clinical trials of new therapies for PH with imaging outcomes |
| Start Year | 2014 |
| Description | University of British Columbia |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Implementation of xenon MRI pulse sequences on UBC scannes |
| Collaborator Contribution | Evaluation of Sheffield MRI protocols at a new clinical site |
| Impact | Research ongoing |
| Start Year | 2020 |
| Description | University of Kiel xenon MRI |
| Organisation | University Hospital Schleswig-Holstein -Kiel |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Enabled xenon polariser at Kiel university for medical and porous media research |
| Collaborator Contribution | New site for xenon MRI |
| Impact | Member of German porous media NMR researhc consortium |
| Start Year | 2020 |
| Description | University of Manchester /Wythenshawe Hospital xenon polariser and MRI infrastructure collaboration |
| Organisation | University of Manchester |
| Department | Manchester Business School |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Loan of a xenon polariser and expertise setting up a new clinical site in xenon MRI |
| Collaborator Contribution | Recipeint clinical site keen to establish technology for lung imaging |
| Impact | None yet |
| Start Year | 2019 |
| Description | UoS / GE Healthcare prosperity partnership |
| Organisation | GE Healthcare Limited |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Academic IP and knowhow for low TRL physics and engineering research for hyperpolarised, lung and MRI technologies |
| Collaborator Contribution | Engineering knowhow and IP for MRI scannner engineering |
| Impact | EPSRC prosperity partnership award |
| Start Year | 2012 |
| Description | Xenon MRI technology enabling |
| Organisation | Columbia University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Enabled xenon MRI technology with installation of Sheffield xenon polarisers at Papworth hospital, UCL, Columbia University, NYC, Kiel University , University of Oxford, AArhus university , Manchester University / Wyhenshawe Hospital |
| Collaborator Contribution | Engineering expertise Xenon hyperppolarisation MRI sequence integration to scanners |
| Impact | First xenon lung images acquired at papworth 2020 first images at Aarhus 2020 first images at Columbia 2020 first COVID images at Oxford |
| Start Year | 2015 |
| Description | Xenon MRI technology enabling |
| Organisation | Royal Papworth Hospital NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enabled xenon MRI technology with installation of Sheffield xenon polarisers at Papworth hospital, UCL, Columbia University, NYC, Kiel University , University of Oxford, AArhus university , Manchester University / Wyhenshawe Hospital |
| Collaborator Contribution | Engineering expertise Xenon hyperppolarisation MRI sequence integration to scanners |
| Impact | First xenon lung images acquired at papworth 2020 first images at Aarhus 2020 first images at Columbia 2020 first COVID images at Oxford |
| Start Year | 2015 |
| Description | Xenon MRI technology enabling |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Enabled xenon MRI technology with installation of Sheffield xenon polarisers at Papworth hospital, UCL, Columbia University, NYC, Kiel University , University of Oxford, AArhus university , Manchester University / Wyhenshawe Hospital |
| Collaborator Contribution | Engineering expertise Xenon hyperppolarisation MRI sequence integration to scanners |
| Impact | First xenon lung images acquired at papworth 2020 first images at Aarhus 2020 first images at Columbia 2020 first COVID images at Oxford |
| Start Year | 2015 |
| Description | Xenon MRI technology enabling |
| Organisation | University of Kiel |
| Department | Neuropediatric Department Kiel |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Enabled xenon MRI technology with installation of Sheffield xenon polarisers at Papworth hospital, UCL, Columbia University, NYC, Kiel University , University of Oxford, AArhus university , Manchester University / Wyhenshawe Hospital |
| Collaborator Contribution | Engineering expertise Xenon hyperppolarisation MRI sequence integration to scanners |
| Impact | First xenon lung images acquired at papworth 2020 first images at Aarhus 2020 first images at Columbia 2020 first COVID images at Oxford |
| Start Year | 2015 |
| Description | Xenon clinical trails consortium |
| Organisation | Cincinnati Children's Hospital Medical Center |
| Department | Division of Rheumatology |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Founding member of consortium for development , evaluation and standardisation of imaging methods for outcome measures for clinical trials of respiratory therapeutics |
| Collaborator Contribution | evaluation and standardisation of imaging methods for outcome measures for clinical trials of respiratory therapeutic |
| Impact | none yet |
| Start Year | 2015 |
| Title | CONTINUOUS REAL-TIME MONITORING OF BIOMOLECULES IN LIVE SUBJECTS |
| Description | The present disclosure provides materials and methods for the continuous measurement of biomolecules in vivo and in real-time. The present disclosure relates more specifically to using capture agents and detection agents within a microfluidic device to detect and quantify biochemical features of biomarkers, enabling real-time detection and concentration measurements. |
| IP Reference | US2023061218 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | Yes |
| Impact | GE patent |
| Title | NUCLEAR MAGNETIC RESONANCE |
| Description | A passive filter circuit, for simultaneous dual-nuclear magnetic resonance quadrature transmit-receive that is configured to apply to an input a quadrature phase shift of a first polarity at a Larmor frequency of a first nucleus and a quadrature phase difference of a second polarity, that is opposite the first polarity, at the Larmor frequency of a second nucleus |
| IP Reference | WO2022269276 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | Commercial In Confidence |
| Impact | Licenced to RF coil company |
| Title | Nuclear Magnetic Resonance |
| Description | RF coil technology for multi nuclear MRI |
| IP Reference | PCT/GB2022/051618 |
| Protection | Patent / Patent application |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | GB and US patent application pending for RF coil invention |
| Title | Clinical trial of Novartis treatment for COPD using hyper polarise lung MRI as primary outcome measure - Indacaterol/Glycopyrronium on Ventilation and Perfusion in COPD: A Randomized Trial |
| Description | The long-acting ß2-agonist/long-acting muscarinic antagonist (LABA/LAMA) combination indacaterol/glycopyrronium (IND/GLY) elicits bronchodilation, improves symptoms, and reduces exacerbations in COPD. COPD is classically associated with gas exchange impairment. Reduced ventilation, especially to perfused lung regions, may be further decreased during exacerbations, and has also been suggested to be related to disease severity. Ventilation defect is a key driver of impaired gas exchange, which can lead to impaired exercise tolerance, reduced quality of life, and death. The combined effect of a For Review Only LABA/LAMA on regional lung ventilation has not been assessed using hyperpolarized gas magnetic resonance imaging (MRI) before. What This Study Adds to the Field: This study shows for the first time, the positive effect of IND/GLY on ventilated lung volume in COPD using hyperpolarized gas MRI. Furthermore, improvements in ventilation leading to reduced ventilation/perfusion (V/Q) mismatch determined from MRI and accompanied by a trend towards increased diffusing capacity for carbon monoxide suggests that intervention with IND/GLY increases ventilation, improves V/Q ratio, and improves oxygenation. This could be an underlying pharmacodynamic mechanism that helps explain how IND/GLY reduces COPD symptoms and reduces the risk of exacerbations |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Small-scale adoption |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Demonstrated that a multi centre clinical trial of a respiratory therapeutic can be performed with high sensitivity lung imaging outcome measures performed in a single centre |
| URL | https://clinicaltrials.gov/show/NCT02634983 |
| Title | Hyperpolarised gas MRI |
| Description | NIHR, EPSRC, MRC |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | iMPORVED DETECTION OF LUNG DISEASE WITH A SENSITIVE NEW LUNG IMAGING MODALITY |
| Title | Sheffield lung imaging toolkit |
| Description | Graphic use interface for qualitative lung imaging |
| Type Of Technology | Software |
| Year Produced | 2016 |
| Open Source License? | Yes |
| Impact | Transfer to sites in Newcastle, Aarhus and Columbia university New York |
| Title | Sheffield/GE Healthcare clinical lung MRI protocols for download |
| Description | User interface to download Sheffield developed and tested clincial lung MRI protocols for GE MRI scanners |
| Type Of Technology | New/Improved Technique/Technology |
| Year Produced | 2023 |
| Impact | Downloads form around the world |
| URL | https://polaris-sheffield.github.io/sheffield-lung-protocol/ |
| Description | BBC features on xenon MRI in long COVID lung disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC TV, RADIO and web coverage and Yorkshire TV / Scottish TV features on work demonstrating xenon MRI sensitivity to covid lung disease |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.bbc.co.uk/news/health-60154398 |
| Description | British chapter ISMRM meeting 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | British chapter ISMRM meeting 2019 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Deputy Editor of Journal of Magnetic Resonance Imaging |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Deputy Editor of Journal of Magnetic Resonance Imaging. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Hot topic talk at European Respiratory society |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary hot topic talks at European Respiratory Society on xenon lung MRI in 2021 and 2022 |
| Year(s) Of Engagement Activity | 2022 |
| Description | ISMRM workshop on value 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | ISMRM workshop on value 2019 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited talk to NIHR academic on collaborating with industry |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited talk to NIHR academic on collaborating with industry |
| Year(s) Of Engagement Activity | 2019 |
| Description | Member of Fleischner society, white paper writitng committee on PH imaging |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Member of Fleischner society, white paper writitng committee on PH imaging |
| Year(s) Of Engagement Activity | 2018 |
| Description | PING 2017 meeting in Utah |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | PING 2017 meeting in Utah |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.physics.utah.edu/ping/ |
| Description | Plenary Invited speaker |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary talk at the British Chapter ISMRM meeting in Aberdeen |
| Year(s) Of Engagement Activity | 2023 |
| Description | Plenary lecture Euromar 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary lecture at European Magnetic Resonance meeting in Krakow 2017 |
| Year(s) Of Engagement Activity | 2017 |
| Description | Plenary lecture ISMRM |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary lecture on xenon MRI at ISMRM meeting |
| Year(s) Of Engagement Activity | 2016 |
| Description | Upenn lung imaging meeting 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Upenn lung imaging meeting 2019 |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.med.upenn.edu/fmig-workshop-lung/ |
| Description | plenary talks at British Thoracic Society 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | plenary talks at British Thoracic Society 2019 |
| Year(s) Of Engagement Activity | 2019 |